PulseAugur
EN
LIVE 09:57:32

Vilya-1: New AI model advances macrocycle drug design

Researchers have introduced Vilya-1, a novel deep learning model designed for the prediction and design of macrocycle structures. This all-atom foundation model addresses limitations in current computational methods by accurately sampling relevant conformations and predicting properties like membrane permeability across diverse chemical spaces. Vilya-1 demonstrates improved geometric accuracy compared to existing physics-based and deep-learning approaches, enabling the design of new macrocycles with specific chemical and structural profiles for therapeutic development. AI

IMPACT Accelerates the design and development of novel macrocycle therapeutics by improving computational modeling accuracy and generative capabilities.

RANK_REASON The item describes a new scientific paper detailing a novel AI model for a specific scientific domain. [lever_c_demoted from research: ic=1 ai=1.0]

Read on arXiv cs.LG →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Vilya-1: New AI model advances macrocycle drug design

COVERAGE [1]

  1. arXiv cs.LG TIER_1 English(EN) · Vilya Research, :, Pascal Sturmfels, Milad Salem, Naozumi Hiranuma, Stephen Rettie, Xiaoliang Pan, Benjamin D. Sellers, Adam P. Moyer, Patrick J. Salveson, Ivan Anishchanka ·

    Vilya-1: An all-atom foundation model for macrocycle structure prediction and design

    arXiv:2607.09998v1 Announce Type: new Abstract: Macrocyclic peptides are an increasingly important therapeutic modality, but existing computational methods for modeling their structures and properties are limited in scope and do not generalize well across the synthetically access…